Literature DB >> 24553912

GPER functions as a tumor suppressor in triple-negative breast cancer cells.

Christine Weißenborn1, Tanja Ignatov, Hans-Joachim Ochel, Serban Dan Costa, Ana Claudia Zenclussen, Zoya Ignatova, Atanas Ignatov.   

Abstract

BACKGROUND: The orphan, membrane-bound estrogen receptor (GPER) is expressed at high levels in a large fraction of breast cancer patients and its expression is favorable for patients' survival.
METHODS: We investigated the role of GPER as a potential tumor suppressor in triple-negative breast cancer cells MDA-MB-231 and MDA-MB-468 using cell cycle analysis and apoptosis assay. The constitutive activity of GPER was investigated.
RESULTS: GPER-specific activation with G-1 agonist inhibited breast cancer cell growth in concentration-dependent manner via induction of the cell cycle arrest in G2/M phase, enhanced phosphorylation of histone H3 and caspase-3-mediated apoptosis. Analysis of the methylation status of the GPER promoter in the triple-negative breast cancer cells and in tissues derived from breast cancer patients revealed that GPER amount is regulated by epigenetic mechanisms and GPER expression is inactivated by promoter methylation. Furthermore, GPER expression was induced by stress factors, such as radiation, and GPER amount inversely correlated with the p53 expression level.
CONCLUSIONS: Overall, our results establish the protective role in breast cancer tumorigenesis, and the cell surface expression of GPER makes it an excellent potential therapeutic target for triple-negative breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24553912     DOI: 10.1007/s00432-014-1620-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  50 in total

1.  The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner.

Authors:  Cheng Wang; Xiangmin Lv; Chao Jiang; John S Davis
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

2.  MethPrimer: designing primers for methylation PCRs.

Authors:  Long-Cheng Li; Rajvir Dahiya
Journal:  Bioinformatics       Date:  2002-11       Impact factor: 6.937

3.  GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERα) phosphorylation signals.

Authors:  Fei Gao; Xinghong Ma; Alicia B Ostmann; Sanjoy K Das
Journal:  Endocrinology       Date:  2011-02-08       Impact factor: 4.736

4.  The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.

Authors:  Adele Vivacqua; Daniela Bonofiglio; Anna Grazia Recchia; Anna Maria Musti; Didier Picard; Sebastiano Andò; Marcello Maggiolini
Journal:  Mol Endocrinol       Date:  2005-10-20

5.  In vivo effects of a GPR30 antagonist.

Authors:  Megan K Dennis; Ritwik Burai; Chinnasamy Ramesh; Whitney K Petrie; Sara N Alcon; Tapan K Nayak; Cristian G Bologa; Andrei Leitao; Eugen Brailoiu; Elena Deliu; Nae J Dun; Larry A Sklar; Helen J Hathaway; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz
Journal:  Nat Chem Biol       Date:  2009-06       Impact factor: 15.040

Review 6.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

7.  Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4.

Authors:  S W Tam; J W Shay; M Pagano
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

8.  The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population.

Authors:  Wen-Hung Kuo; Li-Yun Chang; Daisy Li-Yu Liu; Hsiao-Lin Hwa; Jen-Jen Lin; Po-Huang Lee; Chiung-Nien Chen; Huang-Chun Lien; Ray-Hwang Yuan; Chia-Tung Shun; King-Jen Chang; Fon-Jou Hsieh
Journal:  Taiwan J Obstet Gynecol       Date:  2007-06       Impact factor: 1.705

9.  Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.

Authors:  Rainer Girgert; Günter Emons; Carsten Gründker
Journal:  Breast Cancer Res Treat       Date:  2012-07       Impact factor: 4.872

10.  Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells.

Authors:  A Chimento; I Casaburi; M Bartucci; M Patrizii; R Dattilo; P Avena; S Andò; V Pezzi; R Sirianni
Journal:  Cell Death Dis       Date:  2013-08-01       Impact factor: 8.469

View more
  22 in total

Review 1.  GPER modulators: Opportunity Nox on the heels of a class Akt.

Authors:  Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-08       Impact factor: 4.292

Review 2.  Recent Advances on the Role of G Protein-Coupled Receptors in Hypoxia-Mediated Signaling.

Authors:  Rosamaria Lappano; Damiano Rigiracciolo; Paola De Marco; Silvia Avino; Anna Rita Cappello; Camillo Rosano; Marcello Maggiolini; Ernestina Marianna De Francesco
Journal:  AAPS J       Date:  2016-02-10       Impact factor: 4.009

Review 3.  International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators.

Authors:  Eric R Prossnitz; Jeffrey B Arterburn
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 4.  Rewiring of the Endocrine Network in Triple-Negative Breast Cancer.

Authors:  Kaixuan Li; Dongjiang Zong; Jianrong Sun; Danxiang Chen; Minkai Ma; Liqun Jia
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

5.  Assessment of G Protein-Coupled Oestrogen Receptor Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody.

Authors:  Maria Bubb; Anna-Sophia Lieselott Beyer; Pooja Dasgupta; Daniel Kaemmerer; Jörg Sänger; Katja Evert; Ralph M Wirtz; Stefan Schulz; Amelie Lupp
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

6.  A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.

Authors:  Austin O'Dea; Chelsea Sondergard; Patrick Sweeney; Christopher Kent Arnatt
Journal:  ACS Med Chem Lett       Date:  2018-09-04       Impact factor: 4.345

7.  The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo.

Authors:  W Wei; Z-J Chen; K-S Zhang; X-L Yang; Y-M Wu; X-H Chen; H-B Huang; H-L Liu; S-H Cai; J Du; H-S Wang
Journal:  Cell Death Dis       Date:  2014-10-02       Impact factor: 8.469

8.  Double-edged role of G protein-coupled estrogen receptor 1 in breast cancer prognosis: an analysis of 167 breast cancer samples and online data sets.

Authors:  Fan Yang; Zhi-Min Shao
Journal:  Onco Targets Ther       Date:  2016-10-25       Impact factor: 4.147

9.  Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.

Authors:  Jing Tian; Yong Wang; Xing Zhang; Qianyao Ren; Rong Li; Yue Huang; Huiling Lu; Jian Chen
Journal:  J Exp Clin Cancer Res       Date:  2017-11-02

Review 10.  GPER Function in Breast Cancer: An Overview.

Authors:  Rosamaria Lappano; Assunta Pisano; Marcello Maggiolini
Journal:  Front Endocrinol (Lausanne)       Date:  2014-05-06       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.